COMMUNIQUÉS West-GlobeNewswire

Lifeward Successfully Closes on Strategic Partnership with Oramed
25/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
LogicMark, Inc. Announces Strong Fourth Quarter and Full Year 2025 Results
25/03/2026
Quarterly Revenue Surges 36% as Gross Margin Expands to 69.8% LOUISVILLE, Ky., March 25, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK) (the “Company”), a provider of personal safety and emergency response systems [...]
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
25/03/2026
GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune [...]
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
25/03/2026
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
25/03/2026
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund [...]
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
25/03/2026
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical [...]
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
25/03/2026
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 [...]
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
25/03/2026
The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026, for gedatolisib in [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
25/03/2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the [...]
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
25/03/2026
- FDA Grants IND Clearance for SER-252 - SER-252 Phase 1b Trial Initiated - Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or [...]
American Nurses Enterprise Launches 2026–2030 Strategic Plan, Charting a Bold New Direction for the Future of Nursing
25/03/2026
Marking ANA's 130th Anniversary, ANE Sets a New Strategic Course to Advance the Nursing Profession SILVER SPRING, MD, March 25, 2026 (GLOBE NEWSWIRE) -- The American Nurses Enterprise (ANE), the unifying force behind [...]
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
25/03/2026
TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026 [...]
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
25/03/2026
Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE [...]
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
25/03/2026
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
25/03/2026
Application to upgrade market tier approved WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive [...]
CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier
25/03/2026
DIJON, France – 25 mars 2026 (18H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie [...]
CROSSJECT appoints Lionel Seltz as Chief Financial Officer
25/03/2026
DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto- [...]

Pages